SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-052776
Filing Date
2024-06-14
Accepted
2024-06-14 13:38:21
Documents
14
Period of Report
2024-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207919-8k_immucell.htm   iXBRL 8-K 28146
2 FOURTH AMENDMENT OF INDENTURE OF LEASE FOR PREMISES LOCATED IN PORTLAND, MAINE B ea020791901ex10-1_immucell.htm EX-10.1 10653
  Complete submission text file 0001213900-24-052776.txt   213430

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20240611.xsd EX-101.SCH 3015
4 XBRL LABEL FILE iccc-20240611_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20240611_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0207919-8k_immucell_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 241044050
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)